نتایج جستجو برای: روش mds

تعداد نتایج: 376977  

Journal: :Cancer cell 2011
Liang Li Min Li Canlan Sun Liton Francisco Sujata Chakraborty Melanie Sabado Tinisha McDonald Janelle Gyorffy Karen Chang Shirong Wang Wenhong Fan Jiangning Li Lue Ping Zhao Jerald Radich Stephen Forman Smita Bhatia Ravi Bhatia

Therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) is a major complication of cancer treatment. We compared gene expression in CD34+ cells from patients who developed t-MDS/AML after autologous hematopoietic cell transplantation (aHCT) for lymphoma with controls who did not develop t-MDS/AML. We observed altered gene expression related to mitochondrial function, metabolism, an...

Journal: :IACR Cryptology ePrint Archive 2014
Daniel Augot Matthieu Finiasz

MDS matrices allow to build optimal linear diffusion layers in block ciphers. However, MDS matrices cannot be sparse and usually have a large description, inducing costly software/hardware implementations. Recursive MDS matrices allow to solve this problem by focusing on MDS matrices that can be computed as a power of a simple companion matrix, thus having a compact description suitable even fo...

Ali Sharifi, Farhad Iranmanesh, Kave Shafiee, Nasrin Saliminiya Tania Dehesh

Introduction: We investigated correlation between the retinal nerve fiber layer (RNFL) thickness and the severity of Parkinson's disease (PD). Methods: In this study, the RNFL thickness of 23 patients with Parkinson’s disease (PD) was compared to normal controls (NCs). PD severity was assessed by the MDS-UPDRS (movement disorder society Unified Parkinson Disea...

Journal: :Blood 2002
Lars Nilsson Ingbritt Astrand-Grundström Kristina Anderson Ingrid Arvidsson Peter Hokland David Bryder Lars Kjeldsen Bertil Johansson Eva Hellström-Lindberg Robert Hast Sten Eirik W Jacobsen

Clonality studies of mature cells suggest that the primary transformation event in myelodysplastic syndrome (MDS) most frequently occurs in a myeloid-restricted progenitor, a hypothesis supported by recent studies of purified CD34(+)Thy1(+) hematopoietic stem cells (HSCs) in cases with trisomy 8 (+8). In contrast, we recently demonstrated that a lymphomyeloid HSC is the target for transformatio...

2017
Karine Z. Oben Sara S. Alhakeem Mary K. McKenna Jason A. Brandon Rajeswaran Mani Sunil K. Noothi Liu Jinpeng Shailaja Akunuru Sanjit K. Dhar Inder P. Singh Ying Liang Chi Wang Ahmed Abdel-Latif Harold F. Stills Jr Daret K. St. Clair Hartmut Geiger Natarajan Muthusamy Kaoru Tohyama Ramesh C. Gupta Subbarao Bondada

Myelodysplastic syndromes (MDS) are a diverse group of malignant clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplastic cell morphology in one or more hematopoietic lineages, and a risk of progression to acute myeloid leukemia (AML). Approximately 50% of MDS patients respond to current FDA-approved drug therapies but a majority of responders relapse with...

Journal: :Blood 2002
Yogen Saunthararajah Ryotaro Nakamura Jun-Mo Nam Jamie Robyn Fausto Loberiza Jaroslaw P Maciejewski Toni Simonis Jeffrey Molldrem Neal S Young A John Barrett

The extent and importance of autoimmune mechanisms in myelodysplastic syndrome (MDS) and the role of immunosuppression in the treatment of this disease are not well defined. We report overrepresentation of HLA-DR2 and its serologic split HLA-DR15 in both MDS and aplastic anemia (AA). Four clinically and ethnically defined patient groups were analyzed. The HLA-DR15 antigen frequencies among Nort...

2015
Abdallah Abou Zahr Ehab Saad Aldin Rami S Komrokji Amer M Zeidan

Myelodysplastic syndromes (MDS) represent a heterogeneous group of acquired clonal hematopoietic disorders characterized by peripheral blood cytopenias, paradoxical BM hypercellularity, ineffective hematopoiesis, and increased risk of leukemic transformation. Risk stratification, using different prognostic scores and markers, is at the core of MDS management. Deletion 5q [del(5q)] MDS is a dist...

2016
Lisa Pleyer Sonja Burgstaller Reinhard Stauder Michael Girschikofsky Heinz Sill Konstantin Schlick Josef Thaler Britta Halter Sigrid Machherndl-Spandl Armin Zebisch Angelika Pichler Michael Pfeilstöcker Eva-Maria Autzinger Alois Lang Klaus Geissler Daniela Voskova Dietmar Geissler Wolfgang R. Sperr Sabine Hojas Inga M. Rogulj Johannes Andel Richard Greil

BACKGROUND The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20-30...

2014
Levi J. Beverly Daniel T. Starczynowski

Myelodysplastic syndromes (MDS) are a collection of hematopoietic stem cell (HSC) disorders that consist of blood cytopenias, marrow dysplasia, and a predisposition to acute myeloid leukemia (AML). Approximately 30% of MDS patients go on to develop aggressive AML. MDS is fatal in a majority of patients as a result of marrow failure, immune dysfunction, and/or transformation to overt leukemia. A...

2011
Vincent Mor Orna Intrator Mark Aaron Unruh Shubing Cai

BACKGROUND The Minimum Data Set (MDS) for nursing home resident assessment has been required in all U.S. nursing homes since 1990 and has been universally computerized since 1998. Initially intended to structure clinical care planning, uses of the MDS expanded to include policy applications such as case-mix reimbursement, quality monitoring and research. The purpose of this paper is to summariz...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید